摘要
慢性乙型肝炎为全球流行性疾病,由乙型肝炎病毒感染引发,可发展为肝硬化、肝衰竭、肝癌等不同阶段肝脏疾病。当前,慢性乙型肝炎肝硬化主要以抗病毒治疗为主,联合免疫治疗和肝脏保护治疗等方案,抗病毒药物可抑制病毒复制缓解疾病进展,肝保护治疗则主要通过抗氧化、抗炎和促进肝细胞再生来减轻肝脏损伤,新兴的治疗方法如基因编辑技术、免疫治疗药物、免疫制剂联合抗病毒以及RNA干扰疗法在预临床和临床研究中也显示出巨大的潜力。本文对现阶段慢性乙型肝炎肝硬化的药物研究进展进行了总结,并对这些治疗方法的研究进展、机制及其临床应用前景进行了详细论述。
Chronic hepatitis B is a global epidemic disease.It is caused by hepatitis B virus infection and can develop into liver disease at different stages such as cirrhosis,liver failure,and hepatocellular carcinoma.At present,chronic hepatitis B cirrhosis is mainly treated with antiviral therapy,combined with immunotherapy and liver protective therapy.Antiviral drugs can inhibit virus replication and alleviate disease progression.Liver protective therapy mainly reduces liver injury by anti-oxidation,anti-inflammation and promoting hepatocyte regeneration.Emerging therapeutic approaches such as gene editing technology,immunotherapy drugs,immune agents combined with antiviral drugs,and RNA interference therapy have also shown great potential in pre-clinical and clinical studies.In this paper,the current research progress of drugs for chronic hepatitis B cirrhosis is summarized,and the research progress,mechanism and clinical application prospect of these treatment methods are discussed in detail.
作者
钟敏
王小泽
杨小莉
Zhong Min;Wang Xiaoze;Yang Xiaoli(Department of Gastroenterology,West China Hospital,Sichuan University,Chengdu 610041,China)
出处
《中国医药》
2024年第11期1737-1741,共5页
China Medicine
基金
四川省国际科技创新合作/港澳台科技创新合作项目(2021YFH0099)。
关键词
慢性乙型肝炎肝硬化
药物治疗
现状分析
Chronic hepatitis B cirrhosis
Drug treatment
Analysis of current situation
